Cancer Family
Mast Cell Neoplasm
CI-CAN-00000257Explore in graph →
HematologicNon-malignant9 active trials2 approved drugs4 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000257Explore in graph →
Clinical trials
101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00449748 | Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis | completed | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03580655 | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | completed | Phase 2 | 107 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 24, 2026 |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03401060 | Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis(DenosuMast) | completed | Phase 3 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04681105 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | completed | Phase 1 | 13 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT00255346 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03770273 | Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis | completed | Phase 2 | 21 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Dec 17, 2024 | clinicaltrials |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | completed | Phase 1 | 282 | Deciphera Pharmaceuticals, LLCINDUSTRY | 6 | Dec 13, 2023 | clinicaltrials |
| NCT02561988 | (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | completed | Phase 1 | 86 | Blueprint Medicines CorporationINDUSTRY | 2 | Mar 17, 2023 | clinicaltrials |
| NCT04978740 | Ocular and Palpebral Manifestations of Mastocytosis (MOOMA) | completed | N/A | 21 | Poitiers University HospitalOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT00001756 | Study of Mast Cell Precursors | completed | — | 202 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 7, 2022 | clinicaltrials |
| NCT04695431 | Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM | completed | — | 317 | Blueprint Medicines CorporationINDUSTRY | 5 | Jan 10, 2022 | clinicaltrials |
| NCT00038675 | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | completed | N/A | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT02620254 | Mast Cell Connect: A Registry for Patients With Mastocytosis | completed | — | 743 | Blueprint Medicines CorporationINDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02761473 | Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations | completed | — | 50 | University of MinnesotaOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01869777 | Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia | completed | N/A | 102 | Wake Forest University Health SciencesOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT01334996 | Use of Tamoxifen in Systemic Mastocytosis | completed | — | 1 | Mayo ClinicOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03406325 | Mast Cell Activation Test in Allergic Disease | completed | — | 19 | Hong Kong Sanatorium & HospitalINDUSTRY | 1 | Apr 9, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00050193 | Cause and Natural Course of Pediatric-Onset Mastocytosis | completed | — | 103 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00814073 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis(AB06006) | completed | Phase 3 | 135 | AB ScienceINDUSTRY | 2 | Dec 3, 2019 | clinicaltrials |
| NCT02503800 | The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy | completed | — | 159 | Meir Medical CenterOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03632811 | Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language(Mc_QoL) | completed | — | 30 | University Hospital, ToulouseOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT02441166 | Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis(EvaTryMS) | completed | N/A | 250 | University Hospital, ToulouseOTHER | 2 | Jul 15, 2019 | clinicaltrials |
| NCT02808793 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 | completed | Phase 1 | 25 | Allakos Inc.INDUSTRY | 1 | Mar 13, 2019 | clinicaltrials |
| NCT01807598 | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 10 | Jason Robert GotlibOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00831974 | Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis | completed | Phase 2 | 23 | AB ScienceINDUSTRY | 0 | Dec 11, 2018 | clinicaltrials |
| NCT01266369 | Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation | completed | Phase 2 | 21 | AB ScienceINDUSTRY | 0 | Dec 10, 2018 | clinicaltrials |
| NCT00233454 | Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia | completed | Phase 2 | 26 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00898079 | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | completed | — | 2,545 | Children's Oncology GroupNETWORK | 6 | Jul 19, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00186628 | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | completed | Phase 2 | 36 | Stanford UniversityOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00006413 | Stem Cell Transplantation to Treat Systemic Mastocytosis | completed | Phase 2 | 25 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00171912 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | completed | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT02380222 | Patient-Reported Outcome Questionnaire for Systemic Mastocytosis | completed | — | 5 | Adelphi Values LLCINDUSTRY | 1 | Jan 10, 2017 | clinicaltrials |
| NCT00336076 | Molecular Mechanisms and Diagnosis of Mastocytosis | completed | — | 136 | University of MichiganOTHER | 1 | Nov 7, 2016 | clinicaltrials |
| NCT01481909 | Study on Mastocytosis for Rupatadine Treatment(SMART) | completed | Phase 2 / Phase 3 | 30 | Marcus MaurerOTHER | 1 | Nov 3, 2016 | clinicaltrials |
| NCT02478957 | Treatment of Indolent Systemic Mastocytosis With PA101 | completed | Phase 2 | 41 | Patara PharmaINDUSTRY | 5 | Sep 29, 2016 | clinicaltrials |
| NCT01297777 | Imatinib in KIT-negative Systemic Mastocytosis | completed | Phase 4 | 10 | Hospital Virgen de la SaludOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01333293 | The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients(XOLMA) | completed | Phase 2 / Phase 3 | 17 | University of ZurichOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00493129 | Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00467792 | Natural History of Urticaria Pigmentosa in Children(UP) | completed | — | 47 | Medical College of WisconsinOTHER | 1 | Dec 8, 2008 | clinicaltrials |
| NCT00001356 | Characteristics of Mast Cells in Mastocytosis | completed | — | 300 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jul 6, 2026source: clinicaltrials